Pancreatitis
Teduglutide improves stool outcomes in children with short bowel syndrome over 96 weeks
Pediatric patients with short bowel syndrome‐associated intestinal failure showed improvements in stool consistency and frequency after receiving treatment with teduglutide for 96 weeks, according to post hoc analysis.
‘Public health crisis’ looms as alcohol-related pancreatitis, ALD rise for young people
Rates of alcohol-associated pancreatitis and alcohol-associated liver disease are rising among adolescents and young adults, especially girls and women, according to findings published in JAMA Network Open.
Novel blood test could be first step to early detection of pancreatic cancer
A novel, rapid blood test demonstrated potential for detecting early-stage pancreatic cancer, according to results of a retrospective study.
The year in lipids: Progress in Lp(a) management and a blow to the ‘HDL hypothesis’
In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events.
‘Significant’ savings with diclofenac vs. indomethacin for post-ERCP pancreatitis
PHILADELPHIA — No significant differences were observed in post-endoscopic retrograde cholangiopancreatography pancreatitis with prophylactic diclofenac vs. indomethacin, with researchers also reporting savings of nearly $133,000.
Plozasiran lowers triglycerides, reduces pancreatitis risk in chylomicronemia
In patients with persistent chylomicronemia, plozasiran, a small interfering RNA therapy, was associated with lower triglyceride levels and reduced risk for pancreatitis, researchers reported at the European Society of Cardiology Congress.
Tirzepatide tied to lower odds for diabetic retinopathy, pancreatitis than GLP-1s
Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.
Plozasiran secures FDA breakthrough status for FCS, closing gap with rival olezarsen
The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, coupled with diet, to decrease triglycerides in patients with familial chylomicronemia syndrome, according to a company release.
Q&A: Petition asks FDA to revise fenofibrate labeling to emphasize no CV outcome benefits
Because the science underpinning medicine evolves so quickly, it is not uncommon for some doctors to manage patients based on old evidence that is no longer a best practice; this is called clinical inertia.
Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome
Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.